Search Results - "Peter Meldgaard"

DNAfusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies by Maansson, Christoffer Trier, Andersen, Emma Roger, Ulhoi, Maiken Parm, Meldgaard, Peter, Sorensen, Boe Sandahl

“…EML4-ALK gene fusions are oncogenic drivers in non-small cell lung cancer (NSCLC), and liquid biopsies containing EML4-ALK fragments can be used to study tumor…”
Get full text

Integration of Cell-Free DNA End Motifs and Fragment Lengths Can Identify Active Genes in Liquid Biopsies by Maansson, Christoffer Trier, Thomsen, Louise Skov, Meldgaard, Peter, Nielsen, Anders Lade, Sorensen, Boe Sandahl

“…Multiple studies have shown that cell-free DNA (cfDNA) from cancer patients differ in both fragment length and fragment end motif (FEM) from healthy…”
Get full text

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays by Weber, Britta, Meldgaard, Peter, Hager, Henrik, Wu, Lin, Wei, Wen, Tsai, Julie, Khalil, Azza, Nexo, Ebba, Sorensen, Boe S

“…Lung cancer patients with mutations in the epidermal growth factor receptor (EGFR) are primary candidates for EGFR-targeted therapy. Reliable analyses of such…”
Get full text

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes by May, Theresa, Clement, Michelle S, Halait, Harkanwal, Kohlmann, Alexander, Kohlmann, Milena, Lai, Jason, Lee, Nitta, Li-Sucholeiki, Xiaocheng, Meldgaard, Peter, Joshi, Snehal, Scudder, Sidney, Shrestha, Neelima, Sorensen, Boe, Kiral, Marilyn, O'Donnell, Patrick

“…Survival rates in non-small cell lung cancer (NSCLC) are low. Detection of circulating tumor DNA in liquid biopsy (plasma) is increasingly used to identify…”
Get full text

Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients by Trier Maansson, Christoffer, Meldgaard, Peter, Stougaard, Magnus, Nielsen, Anders Lade, Sorensen, Boe Sandahl

“…Cell‐free DNA (cfDNA) in blood plasma can be bound to nucleosomes that contain post‐translational modifications representing the epigenetic profile of the cell…”
Get full text

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC by Ulhoi, Maiken Parm, Sorensen, Boe Sandahl, Meldgaard, Peter

“…Abstract Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity…”
Get full text

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP) by Månsson, Christoffer Trier, Vad‐Nielsen, Johan, Meldgaard, Peter, Nielsen, Anders Lade, Sorensen, Boe Sandahl

“…Determination of tumour‐specific transcription based on liquid biopsies possesses a large diagnostic and prognostic potential in non‐small cell lung cancer…”
Get full text

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor by Weber, Britta, Winterdahl, Michael, Memon, Ashfaque, Sorensen, Boe S, Keiding, Susanne, Sorensen, Leif, Nexo, Ebba, Meldgaard, Peter

“…Drugs directed toward the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva®) and gefitinib (Iressa®), are used for the treatment of patients…”
Get more information

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment by Demuth, Christina, Madsen, Anne Tranberg, Weber, Britta, Wu, Lin, Meldgaard, Peter, Sorensen, Boe Sandahl

“…Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often…”
Get full text

Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer by Steiniche, Torben, Georgsen, Jeanette Baehr, Meldgaard, Peter, Deitz, Anne C, Ayers, Mark, Pietanza, M Catherine, Zu, Ke

“…Prevalence of tumor PD-L1 expression in extensive-stage small-cell lung cancer (ES-SCLC) is variable, and data on PD-L2 expression are limited. The prognostic…”
Get full text

PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy by Sorensen, Steffen Filskov, Zhou, Wei, Dolled-Filhart, Marisa, Georgsen, Jeanette Baehr, Wang, Zhen, Emancipator, Kenneth, Wu, Dianna, Busch-Sørensen, Michael, Meldgaard, Peter, Hager, Henrik

“…Abstract BACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1 (PD-L1) expression measured by immunohistochemistry may…”
Get full text

ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach by Nielsen, Lærke Rosenlund, Stensgaard, Simone, Meldgaard, Peter, Sorensen, Boe Sandahl

“…•Minimal residual disease can be identified with a clinically transferable approach.•This approach can detect residual disease independent of ctDNA status pre…”
Get full text

Management of crizotinib therapy for ALK -rearranged non-small cell lung carcinoma: An expert consensus by Cappuzzo, Federico, Moro-Sibilot, Denis, Gautschi, Oliver, Boleti, Ekaterini, Felip, Enriqueta, Groen, Harry J.M, Germonpré, Paul, Meldgaard, Peter, Arriola, Edurne, Steele, Nicola, Fox, Jesme, Schnell, Patrick, Engelsberg, Arne, Wolf, Jürgen

“…Highlights • Crizotinib is a standard of care for ALK-positive lung cancer. • Crizotinib-associated AEs are mostly mild to moderate in severity. • Appropriate…”
Get full text

Intra‐individual variation of circulating tumour DNA in lung cancer patients by Hojbjerg, Johanne A., Madsen, Anne T., Schmidt, Hjordis H., Sorensen, Steffen F., Stougaard, Magnus, Meldgaard, Peter, Sorensen, Boe S.

“…Circulating tumour DNA (ctDNA) has been increasingly incorporated into the treatment of cancer patients. ctDNA is generally accepted as a powerful diagnostic…”
Get full text

18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-Small Cell Lung Cancer Patients: A Comparison of Assessment Methods by Fledelius, Joan, Winther-Larsen, Anne, Khalil, Azza A, Bylov, Catharina M, Hjorthaug, Karin, Bertelsen, Aksel, Frøkiær, Jørgen, Meldgaard, Peter

“…The purpose of this study was to determine which method for early response evaluation with 18F-FDG PET/CT performed most optimally for the prediction of…”
Get full text

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC by Gammelgaard, Kristine Raaby, Vad-Nielsen, Johan, Clement, Michelle Simone, Weiss, Simone, Daugaard, Tina Fuglsang, Dagnæs-Hansen, Frederik, Meldgaard, Peter, Sorensen, Boe Sandahl, Nielsen, Anders Lade

“…Non-small cell lung carcinoma patients with epidermal growth factor receptor (EGFR) mutations are offered EGFR tyrosine kinase inhibitors (TKI) as first line…”
Get full text

Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples by Cho, Jong Ho, Sorensen, Steffen Filskov, Choi, Yoon-La, Feng, Yu, Kim, Tae-Eun, Choi, Heyjoo, Georgsen, Jeanette Baehr, Dolled-Filhart, Marisa, Emancipator, Kenneth, Meldgaard, Peter, Sun, Jong-Mu, Kim, Hong Kwan, Choi, Yong Soo, Shim, Young Mog, Zhou, Wei, Hager, Henrik, Kim, Jhingook

“…Abstract Objectives Programmed death ligand 1 (PD-L1) expression may predict response to anti–programmed death 1 (anti–PD-1) or anti–PD-L1 treatment. There is…”
Get full text

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients by Winther-Larsen, Anne, Fledelius, Joan, Demuth, Christina, Bylov, Catharina M, Meldgaard, Peter, Sorensen, Boe S

“…Abstract INTRODUCTION : Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a treatment option in the second- or third-line…”
Get full text

Gene Expression of the EGF System—a Prognostic Model in Non–Small Cell Lung Cancer Patients Without Activating EGFR Mutations by Sandfeld-Paulsen, Birgitte, Folkersen, Birgitte Holst, Rasmussen, Torben Riis, Meldgaard, Peter, Sorensen, Boe S

“…Abstract OBJECTIVES: Contradicting results have been demonstrated for the expression of the epidermal growth factor receptor ( EGFR ) as a prognostic marker in…”
Get full text

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy by Kassem, Moustapha, Meldgaard, Peter, Safwat, Akmal A., Demuth, Christina, Aggerholm-Pedersen, Ninna, Sandahl Sorensen, Boe

“…Background. One of the major challenges affecting sarcoma treatment outcome, particularly that of metastatic disease, is resistance to chemotherapy…”
Get full text